UnknownNot Applicable

Screening of Serum Exosomal miRNA as a Biomarker for Ocular Muscle Myasthenia Gravis

China160 participantsStarted 2023-07-04

Plain-language summary

Ocular muscle myasthenia gravis (Ocular Myasthenia Gravis, OMG) has a high incidence and is difficult to diagnose. It is very necessary to find specific diagnostic indicators for OMG. By collecting peripheral blood of OMG, systemic myasthenia gravis and healthy people, extract miRNAs derived from exosomes in the serum and perform high-throughput sequencing, then use bioinformatics analysis methods to screen specifically expressed miRNAs as biomarkers for OMG diagnosis .

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical manifestations: fluctuating myasthenia; * neostigmine test positive; ③ AChR-Ab, Musk-Ab, LRP4-Ab antibodies positive; ④repetitive nerve stimulation or single fiber EMG Positive (comply with the first one of the above diagnostic criteria and any one of the other three, and at the same time exclude ophthalmoplegia caused by other diseases, the diagnosis can be confirmed). Exclusion Criteria: ①Combined with other autoimmune diseases or other inflammatory diseases; ②Patients with tumorous diseases; * Received targeted biologics, intravenous gamma globulin, plasma exchange therapy within three months before treatment; ④Pregnancy Status or lactation

What they're measuring

A specific miRNA maybe miR-340-5p，miR-106b-5p or miR-27a-3p is a biological marker for diagnosis of OMG

Timeframe: 12,2022

Trial details

NCT IDNCT05888558

SponsorFirst Affiliated Hospital of Jinan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-03-31

View on ClinicalTrials.gov More Myasthenia Gravis trials